 |
JOURNAL TOOLS |
| eTOC |
| To subscribe |
| Submit an article |
| Recommend to your librarian |
ARTICLE TOOLS |
| Publication history |
| Reprints |
| Permissions |
| Cite this article as |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
LETTERS TO THE EDITOR
Minerva Medica 2018 October;109(5):403-5
DOI: 10.23736/S0026-4806.18.05564-7
Copyright © 2018 EDIZIONI MINERVA MEDICA
language: English
Triple therapy: worth the risk?
Bernhard WERNLY 1, Michael LICHTENAUER 1, Uta C. HOPPE 1, Alexander LAUTEN 2, Eliano P. NAVARESE 3, 4, 5, Christian JUNG 6 ✉
1 Department of Cardiology, Clinic of Internal Medicine II, Paracelsus Medical University of Salzburg, Salzburg, Austria; 2 Department of Cardiology, Charité - Universitaetsmedizin Berlin, University Heart Center, German Center for Cardiovascular Research (DZHK), Berlin, Germany; 3 Interventional Cardiology and Cardiovascular Medicine Research, Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Falls Church, VA, USA; 4 SIRIO MEDICINE, Research Network, Falls Church, VA, USA; 5 Cardiovascular Institute, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland; 6 Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany